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ABSTRACT
Endoglin is a transmembrane glycoprotein expressed in vascular
endothelium that plays a key role in angiogenesis. Mutations in the
endoglin gene (ENG) cause hereditary hemorrhagic telangiectasia
type 1 (HHT1), characterized by arteriovenous malformations
(AVMs) in different organs. These vascular lesions derive from
abnormal processes of angiogenesis, whereby aberrant vascular
remodeling leads to focal loss of capillaries. Current treatments for
HHT1 include antiangiogenic therapies. Interestingly, a circulating
form of endoglin (also known as soluble endoglin, sEng),
proteolytically released from the membrane-bound protein and
displaying antiangiogenic activity, has been described in several
endothelial-related pathological conditions. Using human and
mouse endothelial cells, we find that sEng downregulates several
pro-angiogenic and pro-migratory proteins involved in
angiogenesis. However, this effect is much reduced in endothelial
cells that lack endogenous transmembrane endoglin, suggesting
that the antiangiogenic activity of sEng is dependent on the
presence of endogenous transmembrane endoglin protein. In fact,
sEng partially restores the phenotype of endoglin-silenced
endothelial cells to that of normal endothelial cells. Moreover,
using an established neonatal retinal model of HHT1 with depleted
endoglin in the vascular endothelium, sEng treatment decreases the
number of AVMs and has a normalizing effect on the vascular
phenotype with respect to vessel branching, vascular density and
migration of the vascular plexus towards the retinal periphery. Taken
together, these data show that circulating sEng can influence
vascular development and AVMs by modulating angiogenesis, and
that its effect on endothelial cells depends on the expression of
endogenous endoglin.
This article has an associated First Person interview with the first
author of the paper.
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INTRODUCTION
Endoglin is a homodimeric transmembrane glycoprotein that acts
as an auxiliary receptor for members of the transforming growth
factor-β (TGF-β) family of cytokines. It is expressed primarily in
vascular endothelium, but also in mesenchymal cells, and plays a
key role in vascular physiology, including angiogenesis and
vascular remodeling (ten Dijke and Arthur, 2007; López-Novoa
and Bernabeu, 2010; Núñez-Gómez et al., 2017; Redgrave et al.,
2017; Ruiz-Llorente et al., 2017). In humans, there are two different
protein isoforms, the predominantly expressed L-endoglin, and
the minor isoform S-endoglin, generated by alternative splicing
(Gougos and Letarte, 1990; Bellón et al., 1993; Blanco and
Bernabeu, 2011). Both endoglin isoforms are identical in their
extracellular and transmembrane regions, but they differ from each
other in their cytoplasmic domain (Bellón et al., 1993). In addition
to these two membrane-bound proteins, a circulating form of
endoglin, originally named as soluble endoglin (sEng) (Venkatesha
et al., 2006; Gregory et al., 2014), containing the extracellular
region has been described. Circulating sEng is shed from
membrane-bound endoglin by the proteolytic activity of the
matrix metalloprotease 14 (MMP14 or MT1) (Hawinkels et al.,
2010; Valbuena-Díez et al., 2012) and can be released from the
placenta in exosomes enriched with certain sphingomyelin species,
upon clustering with MMP14 (Ermini et al., 2017). However, the
specific nature of the circulating sEng, whether as an individual
soluble protein or complexed within exosomes, is still not fully
understood. Shedding of sEng can be triggered by inflammation,
tumor necrosis factor-α (TNF-α), endothelial injury or anti-
endoglin antibodies (Li et al., 2003; Sunderland et al., 2011;
Kumar et al., 2014; Gallardo-Vara et al., 2016). High levels of sEng
have been reported in several endothelium-related pathological
conditions (Bernabeu et al., 2009; Blázquez-Medela et al., 2010;
Oujo et al., 2013; Gregory et al., 2014). Among these, markedly
elevated levels of sEng are found in pre-eclampsia, a disease of high
incidence in pregnant women which, if left untreated, can lead to the
death of mother and baby (Venkatesha et al., 2006). Pre-eclampsia
is characterized by hypertension and proteinuria associated with
endothelial dysfunction. Several lines of evidence support
a pathogenic role of sEng in pre-eclampsia, including
antiangiogenic activity, increased vascular permeability and
hypertension (Venkatesha et al., 2006; Hawinkels et al., 2010;
Valbuena-Díez et al., 2012). Also, sEng has pro-inflammatory
activity via nuclear factor kappa-light-chain-enhancer of activated B
cells (NFκB) and interleukin-6 (IL6) (Varejckova et al., 2017), and
can modulate inflammation-associated leukocyte adhesion and
transmigration (Rossi et al., 2013). Studies in transgenic animals
overexpressing human sEng suggest that sEng also contributes to
endothelial dysfunction (Jezkova et al., 2016; Rathouska et al.,
2017). Despite its critical importance in vascular pathology, theReceived 28 February 2018; Accepted 29 July 2018
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molecular mechanism of action of sEng remains poorly understood.
It has been postulated that sEng activity is based on its capacity
to antagonize the function of membrane-bound endoglin. For
example, sEng binds to bone morphogenetic protein 9 (BMP9 or
GDF2), a member of the TGF-β family, with high affinity
(Castonguay et al., 2011; Alt et al., 2012; Saito et al., 2017) and
this can lead to sequestration of BMP9, preventing its binding to
surface endoglin and the subsequent downstream intracellular
signaling of the TGF-β receptor complex (Venkatesha et al., 2006;
Hawinkels et al., 2010; Gregory et al., 2014). Also, both membrane-
bound endoglin and sEng contain an accessible arginine-glycine-
aspartic acid (RGD) sequence, which is a consensus binding motif
for integrin recognition (Gougos and Letarte, 1990; Saito et al.,
2017), and it has been shown that sEng can inhibit integrin-
mediated cell adhesion to endothelial endoglin, likely by competing
with its binding to integrins (Rossi et al., 2013, 2016). Nevertheless,
the exact molecular mechanisms of action of sEng remain to be
elucidated.
Endoglin plays a key role in endothelial cells (ECs), as shown by
numerous in vitro and in vivo studies. Roles include regulating cell
proliferation and migration, actin cytoskeleton, endothelial nitric
oxide synthase (eNOS) expression and activity, endothelial cell
permeability, leukocyte extravasation, vessel maturation, arterial
and venous specification, and vessel diameter in response to flow
(López-Novoa and Bernabeu, 2010; Núñez-Gómez et al., 2017;
Rossi et al., 2013, 2016; Mahmoud et al., 2010; Jerkic and Letarte,
2015; Baeyens et al., 2016; Sugden et al., 2017; Jin et al., 2017). In
addition, mutations in the human endoglin gene (ENG) are the
underlying cause of hereditary hemorrhagic telangiectasia (HHT)
type 1 (HHT1), an autosomal-dominant disorder characterized by
the presence of arteriovenous malformations (AVMs) in different
organs (McAllister et al., 1994; Abdalla and Letarte, 2006; Shovlin,
2010). It has been postulated that the vascular lesions derive from
abnormal processes of angiogenesis and vascular remodeling,
leading to focal loss of capillaries and, as a consequence, a direct
connection between venules and arterioles (Wetzel-Strong et al.,
2017; Cunha et al., 2017). The current treatments for HHT1 include
several antiangiogenic therapies (Ruiz-Llorente et al., 2017;
Ardelean and Letarte, 2015). Interestingly, sEng displays
antiangiogenic activity (Hawinkels et al., 2010; Venkatesha et al.,
2006), but its putative role in AVM formation and treatment has not
yet been explored.
In this study, we find that sEng downregulates several pro-
angiogenic and pro-migratory proteins involved in angiogenesis,
and this effect is dependent on the presence of endogenous
transmembrane endoglin. Furthermore, using an inducible endoglin
(Eng) knockout (KO) animal model, we show that sEng treatment
decreases the number of AVMs in the neovascularized retina. Taken
together, this work reveals, for the first time, the context-dependent
role of sEng in regulating angiogenesis and vascular pathogenesis.
RESULTS
sEng inhibits endothelial tubulogenesis and cell migration
The effect of sEng on tubulogenesis and in wound healing assays
was analyzed in cultured human umbilical vein-derived endothelial
cells (HUVECs) using a physiological range of sEng
concentrations: low (1-10 ng/ml) and mid to high concentrations
(40-100 ng/ml). For 3D tubulogenesis assays, HUVECs were
cultured on vascular endothelial growth factor (VEGF)-containing
Matrigel, and treated with increasing concentrations of sEng
(Fig. 1A). After 6 h of culture with sEng, a dose-dependent
inhibition of tubular network formation was observed, compared
with control HUVECs without sEng treatment. This inhibition was
most evident at doses of 40 ng/ml and 100 ng/ml sEng. Next, cell
migration experiments were performed by measuring the
endothelial ‘scratch wound’ closure of HUVECs monolayers over
time (Fig. 1B). Under normal conditions, without sEng treatment,
the wound was almost closed between 6 h and 8 h (75% and 90%,
respectively). However, at 100 ng/ml sEng, closure was only 35% at
6 h and 60% at 8 h (Fig. 1B), suggesting that sEng induced an
inhibitory effect. Because this type of wound healing assay
measures a combination of cell migration and proliferation, we
also analyzed the individual effect of sEng on HUVEC
proliferation. We found no effect of sEng on cell proliferation
(data not shown), suggesting that the overall changes observed in the
scratch wound assay are mainly due to inhibition of cell migration
by sEng. Our observations that sEng inhibits both endothelial cell
tubulogenesis and migration are in agreement with the reported
antiangiogenic activity in vivo of sEng, including the inhibition of
VEGF-induced blood vessel formation and sprouting (Venkatesha
et al., 2006; Hawinkels et al., 2010; Castonguay et al., 2011).
sEng affects the expression of soluble proteins related to
angiogenesis in HUVECs and MLECs
To investigate possible molecular mechanisms underlying the
antiangiogenic activity of sEng, conditioned media from HUVECs
andmouse lung endothelial cells (MLECs) were analyzed following
treatment with sEng. Changes in the secreted angiogenic protein
profile were assessed using angiogenesis-specific antibody arrays.
Upon treatment with sEng, HUVECs and MLECs reduced the
expression of 15 of 55 (HUVECs), and 19 of 53 (MLECs),
angiogenic proteins present in both human and mouse arrays
(Table S1A). Most of the downregulated proteins have pro-
angiogenic properties, consistent with the antiangiogenic and
antimigratory effects of sEng observed above. Ascertaining which
angiogenesis-related proteins were downregulated in both cell types
was partly limited by the fact that the arrays had only 72% proteins
common to both human and mouse panels. Nevertheless, sEng
treatment led to significant downregulation of three pro-angiogenic
proteins in both human and mouse ECs [insulin-like growth factor-
binding protein 1 (IGFBP-1) and 2 (IGFBP-2), and platelet-derived
endothelial cell growth factor (PD-ECGF)] (Fig. 2A; Table S1A).
An additional six proteins [endothelin, CXCL-4 (PF4), dipeptidyl
peptidase 4 (DPP4), heparin binding-like epidermal growth factor
(HB-EGF), platelet-derived growth factor (PDGF-AA or PDGFA)
and thrombospondin-2 (TSP-2 or THBS2)] appeared to be reduced
in both human andmouse ECs, but reached statistical significance in
only one cell type (Fig. 2A; Table S1A). In contrast to the striking
decrease in pro-angiogenic proteins following sEng treatment, only
two proteins in HUVECs and none in MLECs were significantly
increased in response to sEng (Table S1B). Interestingly, maspin,
one of the upregulated proteins, displayed angioinhibitory activity,
in line with an antiangiogenic effect of sEng treatment.
sEng regulates the secretion of angiogenic proteins and this
effect is dependent on endoglin gene expression
To determine whether sEng treatment had a similar antiangiogenic
effect on endoglin-deficient cells, as a model of HHT1, we used a
MLEC line isolated from Engfl/fl;RosaCreERT mice (Anderberg
et al., 2013). The efficiency of 4-OH-tamoxifen-induced endoglin
gene silencing in these MLECs was confirmed by RT-PCR and
immunostaining (Fig. S1). Differentially expressed angiogenic
proteins from Eng-KO and control MLECs, with and without
treatment with sEng, were determined using the mouse angiogenic
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protein array (Table S2). Eng-KO MLECs show altered expression
of many angiogenic proteins compared with controls, in line with
the known importance of endoglin in angiogenesis. However, sEng
treatment normalizes several of these differences back to control
levels. Of eight angiogenic proteins significantly downregulated in
Eng-KO MLECs (including endogenous Eng), one was restored to
normal values upon treatment with sEng, whereas there was a
similar trend for several other proteins (Table S2). These include
heparin-binding EGF-like growth factor (HB-EGF), involved in
vascular remodeling; the chemokine (C-X-C motif ) ligand 1
(CXCL1), involved in angiogenesis, arteriogenesis, inflammation,
and wound healing; pentraxin-3 (PTX3), an acute-phase-response
protein that regulates angiogenesis after ischemia; and proliferin, a
prolactin/growth hormone-like peptide with angiogenic properties.
In addition, expression of angiogenin, a ribonuclease with potent
proangiogenic activity, and placental growth factor (PlGF or PGF),
a VEGF family member involved in angiogenesis and
vasculogenesis, was increased towards normal levels following
sEng treatment. Similarly, of three proteins significantly
upregulated in Eng-KO MLECs, two were reduced to normal
levels by sEng. These were coagulation factor III, also known as
tissue factor (TF), involved in the initial steps of blood coagulation,
and PD-ECGF, a thymidine phosphorylase which promotes
angiogenesis in vivo and stimulates the growth of ECs in vitro.
Several other upregulated proteins, including the pro-inflammatory
chemokine MCP-1 (CCL2), showed a similar trend of restoration
Fig. 1. Effect of sEng on tubulogenesis and wound
healing. (A) HUVECs were incubated on Matrigel plates
at 37°C in VEGF-enriched EBM2/EGM2 medium
containing increasing doses of sEng (0-100 ng/ml). The
cord network formation was visualized by taking pictures
at different times up to 6 h after cell plating. The
appearance of a complete network is achieved by 6 h in
untreated cells or cells treated with 1 ng/ml sEng, while at
higher concentrations of sEng, cells remain in open
tubules with some patches of disorganized and sparse
cells. A representative assay of more than three different
experiments per condition is shown. Scale bars: 100 µm.
The tube density (closed tubes) in the network was
quantified, normalized and represented in the histogram.
*P<0.05; ***P<0.001. (B) Confluent HUVECs
monolayers were disrupted with a pipette tip and treated
with increasing doses of sEng. Photos were taken at
different times and the speed of migration was quantified
by densitometry of the filled space (area within white
dashed lines) in the wound at each time point (bottom
graph). The speed of migration to close the wound of
sEng-treated cells is slower than that of untreated ones.
Experiments were repeated three times and a
representative photograph of each condition is shown.
Scale bars: 100 µm. *P<0.05; **P<0.01.
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towards normal by sEng treatment (Table S2). To confirm this trend,
enzyme-linked immunosorbent assay (ELISA) was used to
ascertain the levels of two upregulated (coagulation factor III and
MCP-1) and two downregulated (HB-EGF and CXCL1) proteins in
Eng-KO MLECs with and without sEng treatment (Fig. 2B). This
analysis confirmed the array data showing that for all four proteins,
sEng significantly altered their levels towards that of controls. Taken
together, these results show that sEng can partially rescue the
angiogenic protein expression imbalance observed in Eng-KO
MLECs, suggesting that sEng can help to compensate for the lack of
endogenous transmembrane endoglin.
sEng inhibits the development of retinal arteriovenous
malformations in an HHT1 murine model
We noticed that many of the genes encoding those proteins
identified in our study (Fig. 2B) are expressed in endothelial cells
during development of the mouse retina (Jeong et al., 2017), which
is awidely used animal model of angiogenesis (Selvam et al., 2018).
In order to assess the effect of sEng on AVM formation during
vascular development, we turned to endothelial-specific tamoxifen-
inducible endoglin KO (Eng-iKOe) mice, which develop AVMs in
the neonatal retina (Mahmoud et al., 2010). Wild-type (WT) and
endothelial-specific Eng-iKOemicewere each intraocularly injected
with sEng in the left eye and vehicle (PBS) in the right eye. Retinal
vasculature was visualized 2 days later by immunofluorescent
staining. At the retinal periphery, where there is active proliferation
of ECs involved in angiogenesis, endoglin expression was increased
compared with the remodeled vessels of the central zone (Fig. 3A;
Fig. S2A). Whereas isolectin staining did not show any significant
difference among the four conditions, endoglin staining was
decreased in Eng-iKOe retinas, compared with WT samples, as
expected (Fig. 3B). We confirmed that sEng treatment did not affect
the level of endoglin staining, when comparing treated versus
untreated mice, thus ruling out a potential artifact owing to sEng
protein accumulation in the vasculature. As previously described
(Mahmoud et al., 2010), loss of endoglin expression in ECs led to
the formation of AVMs within the retinal plexus, delayed
progression of the vascular plexus towards the periphery, and
hyperbranching of the peripheral vessels (Fig. 3). The effect of sEng
treatment on these vascular parameters in WT and Eng-iKOe retinas
was assessed. We show here, for the first time, that treatment with
sEng inhibits vascular plexus migration inWT retinas (Fig. 3C,D), a
finding compatible with the antimigratory and antiangiogenic
activity of sEng observed in vitro (Fig. 1). In contrast, sEng
treatment of Eng-iKOe retinas favors vascular migration, suggesting
a possible mechanism of phenotype ‘normalization’ or ‘rescue’ by
sEng. Normalized vascular density and area covered by alpha
smooth muscle actin (αSMA) staining were higher in Eng-iKOe
(>30%) compared with WT retinas (Fig. 4A,B), and this phenotype
was also partially rescued by sEng treatment, which decreased
vascular density by ∼15%, but had no significant effect on vascular
density ofWT retinas (Fig. 4A). In addition, a significant increase in
caliber or width of veins, but not of arteries, in Eng-iKOe retinas,
compared with WT retinas was observed, although this was not
affected by sEng treatment (Fig. 4C,D).
Compared with WT retinas, Eng-iKOe retinas display more
capillary junctions or branching (Fig. 4E1,E2) in the peripheral
areas, where angiogenesis is more active, and a higher number of
filopodia at the leading edge of migrating tip cells (Fig. 4F1,F2).
However, intraocular treatment with sEng significantly decreased
both branching and filopodia in Eng-iKOe retinas (Fig. 4E1,F1) by
19% (branching) and 17% (filopodia number), thus partially
restoring the phenotype of Eng-iKOe retinas to that of WT.
Based on the observed role of sEng on angiogenesis and vascular
remodeling, we next examined the effect of sEng on AVM formation
in Eng-iKOe retinas (Fig. S2A,B). Treatment with sEng showed a
tendency to decrease the size of AVMs (Fig. S3A,B). Moreover, sEng
significantly decreased the incidence of AVMs in Eng-iKOe retinas
when compared with vehicle treatment (Fig. 5A; Fig. S2A,B).
Overall, the mean number of AVMs was reduced from 4.0 to 2.5
AVMs/retina in Eng-iKOe mice upon treatment with sEng (Fig. 5B).
Fig. 2. Analysis of deregulated proteins upon treatment with sEng.
Differentially expressed secreted angiogenic proteins in HUVECs, MLECs and
Eng-KO MLECs, previously identified in protein arrays, using a cutoff of 0.9 or
1.1 (Tables S1 and S2) were analyzed. (A) Venn diagram representing the
differential protein expression between HUVECs and MLECs upon treatment
with sEng. Among the downregulated proteins, from human and mouse
panels, 12 were found only in HUVECs, 16 were found only in MLECs and
three were found in both HUVECs and MLECs. Within this last set of proteins,
statistical significance in both cell types was found for IGFBP-1, IGFBP-2 and
PD-ECGF. (B) ELISA analysis of differentially secreted angiogenic proteins in
Eng-KO MLECs in the absence (KO) or presence (KO+sEng) of soluble
endoglin compared with control MLECs. Results were normalized to the total
protein concentration in supernatants, and compared with untreated MLECs,
which was given an arbitrary value of 1. For each protein, a minimum of four
different experiments, each in triplicate, were carried out. Fold change (FC)
measurements±s.e.m. and P-values between sEng-treated and untreated KO
MLECs are represented.
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In the neonatal retina, vascular smooth muscle cell (vSMC)
coverage is associated with muscularized arteries, whereas it is
normally absent from veins at this stage of development. We find
Fig. 3. Analysis of vascular markers andmigration in retinas. (A) P7 retinas
from Eng-iKOe and WT mice were stained with isolectin (green) and anti-
endoglin (red), visualized by fluorescence microscopy and analyzed using the
Fiji-ImageJ program. Decreased endothelial endoglin expression and increased
abnormalities in the neonatal vascular plexus from retinas of Eng-iKOe mice
compared with WT animals were observed. The presence of veins (V) and
arteries (A) is indicated. Endoglin staining (red fluorescence) predominates in
veins. Loss of endoglin protein expression in endothelial cells leads to AVMs
(arrows) and hyperbranching in the periphery of retinas (asterisk). White dotted
line boxes in upper panels represent regions enlarged in lower panels. Images
are taken at different magnifications (5×, 10× or 20×). Scale bars: 500 µm (1,2),
400 µm (3,4) and 100 µm (5,6). (B) Quantification of vascular staining in
sEng-intraocularly treated and untreated mice. WT and Eng-iKOe mice were
treatedwith or without sEng, as indicated. Fluorescence intensity of eachmarker
was quantified using the Fiji-ImageJ2 software, and normalized with respect to
WT controls. Endoglin expression is markedly decreased in Eng-iKOe versus
WT retinas, whereas it is not affected by sEng treatment. (***P<0.001). n>20
mice per condition. (C,D) Analysis of vascular migration. (C) Examples of
stained retinas to illustrate the measurement of vascular and retina radius are
shown. Red arrows indicate the vascular radius (measurement from the center
to the edge of the vascular front), whereas purple arrows indicate the retina
radius (measurement from the center to the edge of retina). The black areas
indicate areas in which there has been some breakage in the fragile retina.
Magnification, 5×. Scale bars: 500 µM (D) Quantification of vascular migration.
The vascular radius/retina radius ratio, represented as a percentage, with
respect to the control, was used to quantify vascular migration. Progression of
the vascular plexus to retinal periphery is delayed in Eng-iKOe compared with
WT control retinas, and this delay is partly reversed when Eng-iKOe animals are
treated with sEng. In WT retinas, sEng treatment decreases vascular migration.
***P<0.001 compared with the WT condition; *P<0.05 between the indicated
conditions. n=30 (WT), n=22 (WT+sEng), n=27 (Eng-iKOe) and n=24
(Eng-iKOe+sEng).
Fig. 4. Effect of sEng on vascular parameters of the retinal plexus from
Eng-iKOe mice. WT and Eng-iKOe mice were treated with or without sEng,
as indicated. Retinas were stained with isolectin, anti-endoglin or anti-
αSMA, and the vasculature was visualized by fluorescence microscopy
(Fig. S2). Fluorescence intensity, as well as the area covered by each
marker, were quantified using the Fiji-ImageJ2 software, and normalized
with respect to WT controls. (A) Vascular density was measured in P7
neonatal retinas using isolectin-stained area and normalized to the
corresponding retinal area (RA). n=34 (WT), n=27 (WT+sEng), n=31
(Eng-iKOe) and n=17 (Eng-iKOe+sEng) per condition. As a reference, the
proportion of the retina covered by the vascular plexus, as measured by
isolectin staining (vascular area/RA) is 35±2.5% in the WT. (B) αSMA-
stained area normalized to RA. n=14 (WT), n=10 (WT+sEng), n=13
(Eng-iKOe) and n=13 (Eng-iKOe+sEng). (C,D) Cross-sectional width or
caliber of veins (C) and arteries (D) were measured in at least three
different vessels of each retina, and in three different areas of each vessel
at a similar distance from the center of the retina. n=40 (WT), n=20 (WT
+sEng), n=26 (Eng-iKOe) and n=21 (Eng-iKOe+sEng) per condition.
(E1) Branch points normalized to the corresponding RA. n=36 (WT), n=17
(WT+sEng), n=24 (Eng-iKOe) and n=15 (Eng-iKOe+sEng). (F1) The
number of filopodia, leading edge of migrating tip cells, was normalized to
the selected field of view. n=39 (WT), n=20 (WT+sEng), n=25 (Eng-iKOe)
and n=23 (Eng-iKOe +sEng) per condition. Representative images made
with digital zoom are shown under each condition in E1 and F1. E2 and F2
illustrate examples of the RAs (red outline boxes) in which branch points/
capillary junctions (E2) and filopodia on sprouting cells in the periphery
(F2) were measured. Scale bars: 500 µm. Vessel density (A), specific area
covered by αSMA staining (B), vessel branch points or capillary unions
(E1) and number of sprouts (F1) are all significantly increased in Eng-iKOe
retinas, compared with controls (WT). However, sEng treatment is able to
restore these abnormal parameters, yielding a phenotype similar to that of
WT retinas. (*P<0.05; **P<0.01; ***P<0.001; compared with WT, unless
indicated between specified conditions).
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that the development of AVMs is associated with an ‘arteriolization’
effect owing to increased blood flow through these vessels, leading
to an increased number of αSMA-positive vSMCs at the site of
AVMs (Fig. S2B), as reported (Mahmoud et al., 2010). Of note, we
found a significantly increased expression of αSMA in Eng-iKOe
retinas (compared with WT retinas) that was associated with AVMs
(Fig. 4B; Figs S2B and S3C). Importantly, the area occupied by
vSMCs in Eng-iKOe retinas is significantly decreased after sEng
treatment (Fig. 4B; Fig. S3C), consistent with the reduced caliber,
area (Fig. S3A,B) and number (Fig. 5) of AVMs.
Taken together, the above results (summarized in Table 1) show
that sEng can partially compensate for membrane-bound endoglin
insufficiency to promote rescue of vascular defects in Eng-iKOe
mice.
DISCUSSION
Abnormal levels of sEng are found in several endothelium-related
pathological conditions, including pre-eclampsia (Venkatesha et al.,
2006; Oujo et al., 2013; Gregory et al., 2014), atherosclerosis,
hypercholesterolemia (Blann et al., 1996; Blaha et al., 2008;
Rathouska et al., 2015), diabetes mellitus (Blázquez-Medela et al.,
2010; Ceriello et al., 2015; Emeksiz et al., 2016), hypertension
(Blázquez-Medela et al., 2010), diabetic retinopathy (Malik et al.,
2005), coronary artery disease (Li et al., 2000a; Ikemoto et al., 2012;
Saita et al., 2017), HHT1 (Letarte et al., 2005; Botella et al., 2015),
acute myocardial infarction (Cruz-Gonzalez et al., 2008) and cancer
(Li et al., 2000b; Bernabeu et al., 2009). In many of these diseases,
the deregulated levels of sEng in plasma, serum or urine from
patients have been postulated to be a reliable biomarker for severity
correlation and prognosis. Furthermore, sEng appears to play an
active role in disease pathogenesis. For example, it has been
reported that, in pre-eclampsia, sEng contributes to hypertension
and renal involvement (Venkatesha et al., 2006; Valbuena-Díez
et al., 2012); in atherosclerosis, sEng induces a pro-inflammatory
response, leading to endothelial dysfunction (Varejckova et al.,
2017; Jezkova et al., 2016); and, in cancer, sEng acts as an
antiangiogenic protein by inhibiting the ongoing neoangiogenesis
associated with the growth of solid tumors (Hawinkels et al., 2010;
Castonguay et al., 2011). In spite of the wide range of
pathophysiological effects of sEng reported in the cardiovascular
system, its underlying mechanism of action on ECs is poorly
understood. Of note, the balance between pro- and antiangiogenic
factors in angiogenesis/vascular remodeling is crucial (Potente and
Carmeliet, 2017). One of the aims of this work was to analyze
the levels of angiogenesis-related proteins released from ECs in
the presence of sEng, to provide some insights into the altered
angiogenesis/vascular remodeling processes associated with
increased circulating levels of endoglin. Using human and mouse
ECs, both expressing high levels of membrane-bound endoglin, we
found that sEng induced a protein expression pattern with a
predominant antiangiogenic profile. After sEng treatment, the levels
of secreted pro-angiogenic proteins, such as VEGF, fibroblast
growth factor (FGF), PDGF, IGFBP proteins and thrombospondin,
were all significantly decreased, consistent with the reported
antiangiogenic effect of sEng. In this regard, sEng stimulated the
expression of only one pro-angiogenic protein (leptin) and
the antiangiogenic protein (maspin) (Table S1B). Surprisingly, the
Fig. 5. Effect of sEng treatment on the number of AVMs in Eng-iKOe retinas. AVMs from at least 30 retinas from each group were analyzed. (A) Histogram
representation of the number of AVMs found relative to the number of counted retinas. Retinas treated with sEng show a lower incidence of AVMs than
untreated retinas. (B) Mean number of AVMs corrected for the number of retinas analyzed in Eng-iKOe mice, treated with or without sEng. Values show 95%
confidence intervals. **P<0.01. n=43 (Eng-iKOe) and n=30 (Eng-iKOe+sEng) retinas per condition.
Table 1. Summary of the effects of sEng treatment on different vascular
parameters in Eng-iKOe retinas
Vascular phenotype in Eng-iKOe retinas
Rescue of WT vascular
phenotype upon sEng
treatment in Eng-iKOe retinas
Decreased migration Yes (*)
Decreased length of veins Yes (*)
Decreased length of arteries No (ns)
Increased number of capillary unions Yes (*)
Increased sprouts or tip cells in periphery Yes (***)
Increased vascular density Yes (**)
Increased width of AVMs Trend (ns)
Decreased Eng expression in AVMs Yes (**)
Increased αSMA in AVMs Yes (*)
Increased AVMs area/retina area Trend (ns)
Increased number of AVMs per retina Yes (**)
The most relevant vascular parameters analyzed in retinas of the Eng-KO
genotype are listed. The effects of sEng treatment on those parameters, by
‘rescuing’ a WT phenotype, are indicated. Statistically significant differences
between sEng-treated and untreated Eng-iKOe retinas are indicated. *P<0.05;
**P<0.01; ***P<0.001; ns, not statistically significant.
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cellular response to sEng in the absence of membrane-bound
endoglin yielded different response to ECs expressing normal levels
of endoglin (Tables S1 and S2). Indeed, altered levels of secreted
angiogenic proteins in Eng-iKOe ECs, including coagulation factor
III, PD-ECGF, HB-EGF, CXCL1 and MCP-1, tend to be
normalized towards that of control ECs after treatment with sEng
(Fig. 2B; Table S2B). These results clearly indicate that membrane-
bound endoglin is key in the regulation of the angiogenic signaling
and its absence produces an imbalance that can be compensated by
sEng.
Because endoglin is a component of the TGF-β receptor complex
(López-Novoa and Bernabeu, 2010; Mahmoud et al., 2011), it is
tempting to speculate that the effects of sEng on protein expression
are mediated by this signaling pathway. In this regard, it is worth
mentioning that SERPINE1 (also known as PAI-1), a characteristic
downstream target of the TGF-β route in ECs. Thus, basal levels of
PAI-1 in Eng-iKOe cells tend to be higher than those in control ECs
(Table S2B), a finding compatible with the upregulated expression of
the PAI-1 gene found in gene arrays of ECs derived from HHT
patients (Fernandez-Lopez et al., 2007) and with increased ALK5
(TGFBR1) signaling in the absence of endoglin (Lebrin et al., 2004).
However, sEng treatment tends to restore PAI-1 levels in Eng-iKOe
cells to similar levels of control ECs (Table S2B), potentially by
restoring the normal balance of the TGF-β signaling pathway. Of
note, the extracellular part of endoglin specifically interacts with the
TGF-β type I receptors ALK1 (ACVRL1) and ALK5 and with the
TGF-β type II receptor (Guerrero-Esteo et al., 2002; Blanco et al.,
2005). Also, endoglin is released from the placenta into the maternal
circulation via sphingomyelin (18:0)-enriched exosomes, together
with ALK5 and the TGF-β type II, where it can associate with these
receptors, forming a functional receptor complex and modulating the
vascular effects of TGF-β in the circulation (Ermini et al., 2017).
Although soluble endoglin does not bind on its own to TGF-β1
(Gregory et al., 2014), it is possible that sEng, which contains most of
the extracellular part of endoglin, could bind to the TGF-β receptor
complex, mimicking membrane-bound endoglin and thus
modulating its downstream signaling. This is an interesting
possibility that could explain why in endoglin-silenced ECs, sEng
restores the protein expression pattern of normal endothelial cells, and
in an HHT1 animal model, sEng decreases the number of AVMs.
The extracellular region of endoglin binds with high affinity to
BMP9 (Castonguay et al., 2011; Alt et al., 2012; Saito et al., 2017),
a TGF-β family member involved in the development of blood and
lymphatic vessels (Levet et al., 2013; Chen et al., 2013; Li et al.,
2016) and in endoglin-dependent chemokine responses of ECs
(Young et al., 2012). In addition to HHT1 patients carrying
mutations in endoglin, an HHT-like disorder has also been reported
in patients heterozygous for mutations in BMP9 (Wooderchak-
Donahue et al., 2013), whereas single-allele mutations in the ALK1
gene give rise to HHT2 (Johnson et al., 1996). Accordingly, BMP9,
ALK1 and endoglin proteins participate in a common signaling
pathway also involving the type II receptors BMPRII and ActRII
(Mahmoud et al., 2011; Tillet and Bailly, 2015; Roman and Hinck,
2017; Ruiz-Llorente et al., 2017) (Fig. 6A,B). Thus, in normal ECs
it is possible that upon binding to BMP9, sEng (either alone or in
complex with exosomes), ‘hijacks’ the ligand, prevents its binding
to the receptor complex, and inhibits the downstream intracellular
signaling (Hawinkels et al., 2010; Gregory et al., 2014; Venkatesha
et al., 2006; Wang et al., 2017) (Fig. 6C). However, in endoglin-
silenced ECs, BMP9 cannot bind to membrane endoglin, but can
still associate with sEng (Castonguay et al., 2011; Saito et al., 2017).
Furthermore, because sEng-bound BMP9 can directly interact with
ALK1 (Blanco et al., 2005; Castonguay et al., 2011; Saito et al.,
2017), it can be hypothesized that the effects of BMP9/sEng involve
its interaction with ALK1 to promote proangiogenic ALK1
signaling and decrease the incidence of AVMs (Fig. 6D). As sEng
and the type II receptors BMPRII or ActRII bind to BMP9 in a
mutually exclusive fashion, sEng would be released, potentially
enabling repeated enhancement of signaling. However, further
detailed studies are needed to elucidate the exact mechanism of
action of sEng in this pathway.
As discussed above, sEng displays antiangiogenic activity and
the protein array data suggest that sEng regulates the expression of
different proteins involved in angiogenesis and vascular
remodeling, which are key processes involved in the generation of
AVMs. In addition, using an HHT1 model of ECs, sEng was able to
Fig. 6. Hypothetical model of sEng action on the vasculature. (A,B) In
normal endothelial cells, membrane endoglin is a component of a receptor
complex that contains type I (RI; ALK1), and type II (RII; BMPR2/ActRII) TGF-β
receptors, which can be activated by BMP9, leading to an equilibrium between
pro- and antiangiogenic factors (A). In endoglin-silenced endothelial cells
(Eng-iKOe), BMP9 cannot bind to endoglin and BMP9-dependent signaling is
disturbed, leading to a dysregulated expression of angiogenic factors,
decreased migration during angiogenesis and the presence of AVMs (B).
(C,D) In normal endothelial cells, the circulating extracellular region of endoglin
(sEng) can interact with BMP9, sequestering the ligand, interfering with the
intracellular signaling of the receptor complex and changing the angiogenesis
balance towards a dysregulated state (C). In Eng-iKOe, BMP9 cannot bind to
membrane endoglin, but interacts with sEng, and the resulting BMP9/sEng
complex interacts with the ALK1 receptor on the cell membrane, enhancing the
proangiogenic ALK1 signaling and decreasing the incidence of AVMs (D). The
involvement of endoglin in the TGF-β1/ALK5 signaling pathway of endothelial
cells has been omitted for simplification.
7
RESEARCH ARTICLE Disease Models & Mechanisms (2018) 11, dmm034397. doi:10.1242/dmm.034397
D
is
ea
se
M
o
d
el
s
&
M
ec
h
an
is
m
s
partly restore the protein expression pattern of normal ECs. Because
several antiangiogenic therapies have been used in HHT patients
(Lebrin et al., 2010; Dupuis-Girod et al., 2012, 2016; Albiñana
et al., 2012) to inhibit vascular bleeding produced by the rupture of
AVMs, we analyzed whether sEng could also modulate the
occurrence of AVMs formed in an established mouse model of
HHT1 (Mahmoud et al., 2010; Tual-Chalot et al., 2015). In the
absence of endoglin, retinal vascular development shows delayed
vascular plexus remodeling, increased endothelial cell proliferation,
formation of AVMs, and increased SMA expression in AVMs as a
result of increased flow (Mahmoud et al., 2010). We find that
intraocularly injected sEng promotes rescue of abnormal
vasculature, and decreases the incidence and size of AVMs in this
model (Table 1). Upon sEng treatment, the number of AVMs was
decreased, the number of capillary unions and sprouts of tip cells in
the periphery were normalized, and the vascular density and the
length of veins were restored, with respect to the WT phenotype.
It has been proposed that sEng might play a role in promoting
AVMs (Chen et al., 2009). Patients with sporadic brain AVMs had
higher levels of sEng compared with controls, but membrane-bound
endoglin levels were normal and there was no history of HHT. Our
findings would suggest that sEng acts differently in the presence
of membrane-bound endoglin, compared with cases in which
membrane-bound endoglin is reduced. Interestingly, one of the
hallmarks of HHT1 is the deficient expression of endoglin (Abdalla
and Letarte, 2006; Ruiz-Llorente et al., 2017) and, accordingly, it
could be speculated that addition of exogenous sEng in this context
could have a beneficial effect in counteracting the formation of AVMs.
However, the underlying mechanism of action of sEng in AVM
formation in both sporadic cases and in HHT remains to be elucidated.
In addition to the putative role of sEng in the TGF-β/BMP9
pathway, its function as a modulator of cell adhesion cannot be
excluded. In this regard, the extracellular region of endoglin displays,
within its zona pellucida domain, an RGDmotif, which is a consensus
sequence implicated in integrin-based interactions with other proteins
(Gougos and Letarte, 1990; Saito et al., 2017; Llorca et al., 2007).
Accordingly, it has been shown that sEng can modulate integrin-
mediated cell adhesion involving membrane-bound endothelial
endoglin (Rossi et al., 2013, 2016; Ruiz-Remolina et al., 2017), and
this function might have an impact on the active angiogenesis and
vascular remodeling processes in the neovascularized retina of Eng-
iKOe mice. In this regard, upon an inflammatory stimulus, leukocyte
recruitment to the vasculature involves endothelial endoglin, via
leukocyte integrins (Rossi et al., 2013), as well as BMP9 (Mitrofan
et al., 2017). Because the inflammatory infiltrate of leukocytes appears
to be involved in the vascular remodeling leading to AVMs in HHT
patients (van Laake et al., 2006; Zhang et al., 2016), a role for sEng in
this cell adhesion-dependent process can be postulated (Dingenouts
et al., 2015; Rossi et al., 2015).
Endoglin and ALK1 play a key role in angiogenesis (López-
Novoa and Bernabeu, 2010; Núñez-Gómez et al., 2017; Mahmoud
et al., 2011; Roman and Hinck, 2017), and targeting these proteins
has been used as a therapeutic approach to treat tumor angiogenesis.
For example, TRC105 is a humanized monoclonal antibody against
endoglin that not only binds to membrane-bound endoglin, but is
also able to stimulate shedding of sEng (Kumar et al., 2014; Rosen
et al., 2014). TRC105 is currently used in antiangiogenic therapies
of several types of cancer (Liu et al., 2014; Paauwe et al., 2016).
Moreover, ongoing clinical trials are testing two ALK1-related
pharmacological inhibitors: dalantercept/ACE-041, an ALK1
extracellular domain fusion protein, and PF-03446962, an
antibody against the extracellular domain of ALK1 (de Vinuesa
et al., 2016). Whether sEng can also be used as an antiangiogenic
drug remains to be determined.
Taken together, our results suggest that sEng has context-
dependent effects. In the presence of endogenous transmembrane
endoglin, it has antiangiogenic properties, but, in the absence of
endogenous endoglin, sEng can rescue angiogenic defects in
HHT1. This would suggest that under these latter conditions, sEng
is pro-angiogenic. However, this hypothesis needs to be confirmed
by further investigations on the exact mechanistic role of sEng in the
absence of endogenous endoglin. Although we have shown that
sEng can reduce the generation of AVMs, additional studies are
needed to explore whether sEng is able to regress AVMs once they
have been formed, and whether sEng could be used in the future as a
therapeutic drug for the resolution of AVMs in HHT1 patients.
These studies could also be helpful to better understand the function
of sEng in conditions such as pre-eclampsia, cancer or inflammatory
disease, where sEng is present at high levels.
MATERIALS AND METHODS
Cell culture and treatments
All cells were incubated routinely at 37°C in a humidified atmosphere with
5% CO2. HUVECs were purchased from Lonza and used at early passages
(3-5). HUVECs were grown on 0.2% gelatin (Sigma-Aldrich) pre-coated
plates, in endothelial growth medium (EGM-2) supplemented with 10%
heat-inactivated fetal bovine serum (FBS, Gibco), 2 mM L-glutamine,
100 U/ml penicillin and 100 µg/ml streptomycin (Gibco), unless otherwise
noted. MLECs were derived from Engfl/fl;RosaCreERT mice, as previously
described (Anderberg et al., 2013). Briefly, endothelial cells were
isolated with anti-CD31 (PECAM1)-coated Dynabeads sheep anti-rat IgG
(Invitrogen) after dissociation of the lung tissue with 1 mg/ml collagenase,
and cultured in MV2 endothelial cell basal medium (PromoCell) with 10%
FBS. Treatment with 1 µM 4-OH-tamoxifen for 48 h was used to activate
CreERT, leading to endoglin deletion. Treatments with human recombinant
sEng (R&D Systems), reconstituted in PBS with 0.1% bovine serum
albumin (BSA), were carried out either in serum-free medium or in 2% FBS
medium, as indicated. For angiogenic protein assays, HUVECs or MLECs
(with or without endoglin KO) were incubated with or without 100 ng/ml
sEng for 24 h in EBM-2 or MV2 serum-free medium, respectively.
The resulting culture supernatants were used to evaluate secreted
angiogenic proteins using protein antibody arrays (described below).
Culture supernatants were also analyzed using ELISA kits specific for
mouse CXCL1 (DY453-05), coagulation factor III (DY3178-05), HB-EGF
(DY8239-05) and MCP-1 (DY479-05) from R&D Systems. The
immunoassays were performed according to the manufacturer’s protocol
and measured in a Glomax® Multi Detection System (Promega).
Wound healing and tube formation assays
In vitro scratch wounds were created by scraping confluent HUVEC
monolayers in 24-well plates with a sterile pipette tip. Fresh EBM2
medium supplemented with 2% FBS and EGM2 (Lonza) with different
concentrations of sEng was added, and samples were incubated for up to
10 h. Endothelial cell migration into the denuded area was monitored at 0, 4,
6, 8 and 10 h postwound. The ImageJ program (Schneider et al., 2012) was
used to quantify the wound healing process. For tube formation assays,
HUVECs were seeded on 24-well plates, previously covered with 100 μl
standardMatrigel (BDBioscience) diluted 1:2 in serum-free EBM2medium
supplemented with VEGF-containing EGM2 (Lonza). Samples were
incubated at 37°C in EBM2 medium supplemented with 2% FBS and
EGM2 in the presence of sEng (0-100 ng/ml) for 6 h, as indicated. Images
were taken with an Olympus digital camera, and quantification of closed
tubules was performed using Adobe Photoshop CS3 software.
Angiogenesis protein arrays
Conditioned medium from HUVECs and MLECs cells, previously
incubated with 100 ng/ml sEng in serum-free medium for 24 h, were
used. The relative expression profile of angiogenesis-related proteins were
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quantified using a proteome profiler mouse angiogenesis array kit (ARY
015-mouse; ARY 007-human; R&D Systems) according to the
manufacturer’s instructions. The relative intensities of the spots were
normalized per total protein concentration of each supernatant, measured
with the BCA protein assay kit (Pierce), and by subtracting the background
of the membranes. Each protein array experiment was performed in
triplicate.
Mice and treatments
The Engfl/fl mouse and Eng-iKOe mouse lines have been previously
described (Mahmoud et al., 2010; Allinson et al., 2007). Neonates were
injected subcutaneously with 0.5 mg tamoxifen (Sigma-Aldrich) at
postnatal day (P) 2 and P4 to activate Cdh5-CreERT2, as reported
(Mahmoud et al., 2010). Controls were tamoxifen-treated Engfl/fl
littermates. For intraocular treatments, P5 neonates were anesthetized by
3% isofluorane and intraocularly injected with 0.3 µl of 100 ng/ml sEng in
PBS/0.1% BSA or control solution (PBS/0.1% BSA) in the left and right
eye, respectively, using a Hamilton syringe (80001 10 μl SYR) attached to a
fine needle (Needle PRE-33013 TSK Laboratory).
Whole-mount, immunofluorescence staining and analysis of
different parameters in mouse retinas
Mouse eyes were enucleated immediately postmortem at P7. Retinas were
prepared and stained following the whole-mount immunofluorescence
protocol from Tual-Chalot et al. (2013). Briefly, retinas were fixed in 4%
(wt/vol) paraformaldehyde in PBS and then stained with Alexa Fluor
488-conjugated G. simplicifolia isolectin B4 (Life Technologies).
Immunostaining using antibody against mouse endoglin (MJ7/18,
eBioscience) was detected using an Alexa Fluor 568-conjugated
secondary anti-rat antibody (Thermo Fisher Scientific). Vascular smooth
muscle was detected using anti-αSMA-Cy3 antibody (Sigma-Aldrich).
Stained retinas were flat mounted using ProLong Gold Antifade Mount
medium (Thermo Fisher Scientific) and examined under a Zeiss Axioimager
microscope, and images were analyzed using Zeiss-ZEN software. Analysis
of vascular parameters was performed using Fiji-ImageJ2 software
(Schindelin et al., 2012). Vascular migration was calculated by dividing
the length of the vessel radius by the total length of the retina radius, both
measured from the center of the retina in at least three different directions.
Analysis of the branch points was calculated by counting the closed
capillaries in at least three different areas near the retinal periphery.
Measurements of the number of filopodia, at the leading edge of migrating
tip cells, were normalized to the selected field of view, in at least four
different sections of the retina.
The percentage area covered by isolectin-positive ECs, and αSMA- or
endoglin-positive cells was calculated as the area occupied by the intensity
of each marker normalized by the total retinal vascular area. Nonspecific
staining at the edges of the retina or remnants of the hyaloid vessel were
discarded. The number of AVMs was measured throughout the retina. At
least 15 retinas were analyzed per parameter and per group.
Statistical analysis
Wound healing, tubulogenesis and array data were analyzed by Student’s
t-test. ANOVA test was used for the comparison of more than one group.
Nonparametric data were analyzed using the Kruskal–Wallis test. Variances
between the different groups were determined by the Levene’s test. Post
hoc Tamhane or Bonferroni tests were performed for homogeneous or
nonhomogeneous variances, respectively. Analysis was performed using
SPSS software. All results shown in graphical representations are the mean
of a minimum of three replicates. Data are presented as mean±s.e.m. with
the corresponding P-values.
Ethics
All animal experiments were performed under UK Home Office license,
with approval from the Newcastle University Ethical Review Committee
and following the guidelines of EU Directive 2010/63/UE for animal
experiments. All applicable international, national and/or institutional
guidelines for the care and use of animals were followed.
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